The most expensive mistake in employer benefits: Assuming cancer is 'covered'

While GLP‑1s have dominated budget conversations and boardroom anxiety, cancer costs are accelerating quietly — and far faster. Cancer has always been expensive, but now it's one of the most volatile, complex and quickly accelerating areas of employer risk.

Yet many employers simply assume their cancer benefits are "covered." They offer something — a navigation app, a second‑opinion hotline, a point solution — and believe they've built a strategy.

But offering "something" is not a strategy. And it certainly is not evidence-based care.

A growing ripple effect

Cancer has evolved from a niche benefits concern into a strategic workforce imperative, as prevalence of cancer impacting working-age adults is expected to rise 30% by 2030. 

For employers, the impact of a single diagnosis reverberates far beyond the individual. The ripple effects — emotional strain, productivity disruption, and team instability — are increasingly part of the employer risk equation. Nearly 74% of cancer patients and survivors miss work as a result of their illness, with the majority of those being out for more than four weeks, straining teams and operations.

The financial picture is equally stark. Cancer drugs now account for as much as 25% of total drug spending. In commercial plans, oncology medications drove about 40% of total per‑member per‑month medical spend, with average claims exceeding $4,200 per claim. 

These costs will continue to accelerate, as recent trends indicate. U.S. spending on oncology doubled to $116 billion in just five years, growing at a rate that outpaces inflation and cost increases in most other therapeutic classes. 

Read more:  AI is reshaping jobs, not replacing them

A blind spot in cancer benefits strategies

Despite escalating costs, most employers believe they have cancer benefits covered.  According to Business Group on Health, 88% of large employers rank cancer among their top three health cost drivers, yet only 43% provide comprehensive, specialized cancer solutions. That disconnect reflects a clear gap between perceived coverage and the level of expertise and coordination patients increasingly need.

Cancer treatment is increasingly complex, driven by rapid advances in biomarker science, precision medicine and new therapeutic classes. Yet 80% of cancer care still occurs in community settings, where oncologists face mounting pressure to keep pace with expanding guidelines and cutting-edge treatment options.

At the same time, access to subspecialist expertise remains limited. The U.S. has only 57 NCI‑Designated Comprehensive Cancer Centers across 37 states, meaning most employees will never receive care at — or benefit from — the level of multidisciplinary review that defines today's evidence-based care.

This mismatch creates what can be described as the "access gap." Employees receive compassionate care, but not always care aligned with the latest evidence. That variation in care leads to variation in outcomes — and ultimately, variation in spend.

Why early decisions drive significant cost differences

Cancer is not only expensive; it is highly sensitive to early clinical decisions. Misaligned diagnostic interpretations, treatment sequencing or missed clinical trial opportunities can significantly increase downstream costs.

Industry leaders point to expert second opinions as one of the most effective ways to reduce that variation. Subspecialist review can:

• Confirm diagnosis and staging
• Validate or refine treatment plans
• Identify more appropriate or less invasive options
• Surface clinical trials before treatment begins

These reviews don't replace community oncologists, they support them. And when early decisions are aligned with evidence‑based standards, employers see lower complication rates, fewer avoidable acute‑care episodes and more predictable cost trajectories.

Must-have second opinions

This is why expert second opinions should not be optional. They are foundational risk management. For patients, that first treatment recommendation reverberates through their entire journey. It shapes clinical outcomes, the employee's confidence in their employer and, ultimately, cost. 

A subspecialist‑driven second opinion can confirm diagnosis, refine treatment plans, offer  invasive options and identify clinical trials before treatment begins — adding resources to community oncologists' arsenal in the fight against cancer.

Read more:  Voluntary eldercare benefit is high-demand, low-cost win for employers

What employers should be asking in 2026

There's no question that healthcare costs will continue to accelerate across the board, especially as trends, like GLP-1s, take center stage. But to truly manage the most significant costs, benefits leaders must reassess whether their current strategies reflect the realities of modern cancer care. 

When evaluating plans for 2026 and beyond, they must consider key questions about cancer offerings to ensure their employees are receiving evidence-based care:

• Are employees getting access to evidence-based care early?
• Are second opinions delivered by cancer subspecialists?
• Is multidisciplinary review built into the benefit design?
• Are benefits coordinated across the entire cancer journey, or fragmented across point solutions?
• Can we measure — with claims‑level certainty — whether their cancer benefits are improving outcomes?

No doubt these answers currently vary wildly across organizations. But one trend is clear: Doing nothing different is no longer a neutral choice.

Read more:  Benefit cuts may save employers money, but cost them talent

Evidence-based care is the standard of benefits

As employers prepare for 2026, the conversation must shift from "What cancer benefits do we offer?" to "How do we ensure employees receive care aligned with today's standards?"

Employees expect their organization to respond with clarity, support and high‑quality care pathways when a diagnosis occurs. And with oncology spend rising, workforce expectations changing and clinical complexity accelerating, cancer care is becoming a defining test of whether employer benefits are built for real‑world needs — or simply built for open enrollment.